Idioma:

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kalinsky, Kevin ; Barlow, William E ; Gralow, Julie R ; Meric-Bernstam, Funda ; Albain, Kathy S ; Hayes, Daniel F ; Lin, Nancy U ; Perez, Edith A ; Goldstein, Lori J ; Chia, Stephen K.L ; Dhesy-Thind, Sukhbinder ; Rastogi, Priya ; Alba, Emilio ; Delaloge, Suzette ; Martin, Miguel ; Kelly, Catherine M ; Ruiz-Borrego, Manuel ; Gil-Gil, Miguel ; Arce-Salinas, Claudia H ; Brain, Etienne G.C ; Lee, Eun-Sook ; Pierga, Jean-Yves ; Bermejo, Begoña ; Ramos-Vazquez, Manuel ; Jung, Kyung-Hae ; Ferrero, Jean-Marc ; Schott, Anne F ; Shak, Steven ; Sharma, Priyanka ; Lew, Danika L ; Miao, Jieling ; Tripathy, Debasish ; Pusztai, Lajos ; Hortobagyi, Gabriel N

The New England journal of medicine, 2021-12, Vol.385 (25), p.2336-2347 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Autor: Kalinsky, Kevin ; Barlow, William E ; Gralow, Julie R ; Meric-Bernstam, Funda ; Albain, Kathy S ; Hayes, Daniel F ; Lin, Nancy U ; Perez, Edith A ; Goldstein, Lori J ; Chia, Stephen K.L ; Dhesy-Thind, Sukhbinder ; Rastogi, Priya ; Alba, Emilio ; Delaloge, Suzette ; Martin, Miguel ; Kelly, Catherine M ; Ruiz-Borrego, Manuel ; Gil-Gil, Miguel ; Arce-Salinas, Claudia H ; Brain, Etienne G.C ; Lee, Eun-Sook ; Pierga, Jean-Yves ; Bermejo, Begoña ; Ramos-Vazquez, Manuel ; Jung, Kyung-Hae ; Ferrero, Jean-Marc ; Schott, Anne F ; Shak, Steven ; Sharma, Priyanka ; Lew, Danika L ; Miao, Jieling ; Tripathy, Debasish ; Pusztai, Lajos ; Hortobagyi, Gabriel N
Assuntos: Adult ; Age ; Aged ; Antineoplastic Agents, Hormonal - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological assay ; Biopsy ; Breast Cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - genetics ; Breast Neoplasms - surgery ; Cancer ; Cancer therapies ; Chemotherapy ; Chemotherapy, Adjuvant ; Consent ; Disease-Free Survival ; Endocrine therapy ; Epidermal growth factor ; ErbB-2 protein ; Female ; Gene Expression Profiling ; Hematology ; Humans ; Invasiveness ; Lymph nodes ; Lymphatic Metastasis ; Medical prognosis ; Menopause ; Menstruation ; Middle Aged ; Neoplasm Recurrence, Local - genetics ; Oncology ; Oncology, Experimental ; Population ; Post-menopause ; Postmenopause ; Premenopause ; Prospective Studies ; Receptor, ErbB-2 ; Receptors, Steroid ; Reverse Transcriptase Polymerase Chain Reaction ; Survival ; Treatments in Oncology ; Womens health
É parte de: The New England journal of medicine, 2021-12, Vol.385 (25), p.2336-2347
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Descrição: Five-year invasive disease–free survival was similar among postmenopausal women with hormone-receptor–positive, HER2-negative breast cancer, one to three positive axillary lymph nodes, and a 21-gene recurrence score of 25 or lower who received endocrine-only therapy and those who received chemoendocrine therapy. In premenopausal women, chemoendocrine therapy significantly improved outcomes.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.